PGRN-CGM International Collaborative Studies

Leaders at the National Institutes of Health(NIH) Pharmagenomics Research Network (PGRN) and the RIKEN Center for Genomic Medicine(CGM) in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics. Using genomewide approaches, identify genetic variants that contribute to individual responses to medicines, including rare and serious side effects. The results will help clinicians optimize the safety and effectiveness of drugs for each patient.

Goals

The goals of these international collaborative studies are to facilitate research discoveries of genetic/genomic factors contributing to individual drug effects and adverse reactions, to contribute to the development of personalized medicines, and to directly benefit the healthcare of global populations.

PG Research Network

RIKEN CGM in Japan

"By bringing together our resources, we will advance the understanding of how changes in DNA affect our responses to medicines. Thus we can begin to realize the promise of personalized medicine." Yusuke Nakamura, M.D., Ph.D.

Acknowledgement

This study is supported by the NIH Pharmacogenomics Research Network (PGRN) - RIKEN Center for Genomic Medicine (CGM) Global Alliance.